1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Ardena Inks Agreement to Acquire Catalent’s State-Of-The-Art Facility in Somerset, New Jersey

16 Oct 2024
Admin
News Article

Ardena Inks Agreement to Acquire Catalent’s State-Of-The-Art Facility in Somerset, New Jersey

Overview

Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey.

Impact of Acquisition

This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products, supporting its strategy to become a leading global CDMO offering integrated solutions across the entire pharmaceutical development lifecycle.

Somerset Facility

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena’s existing oral solid expertise.

Acquisition Impact on Ardena

This acquisition also positions Ardena well to expand its bioanalytical services in the US to serve a growing client base driven by an ever-increasing demand for advanced drug development services.
The facility's specialized technologies and analytical capabilities bolster Ardena’s integrated offering, providing comprehensive solutions for pharmaceutical and biotechnology customers on both sides of the Atlantic.

Words from the CEO: Ardena

"Today marks a significant milestone in Ardena’s international growth strategy,"" explains Jeremie Trochu, chief executive officer of Ardena.
"We are thrilled to welcome the talented scientific and operations team from Somerset into the Ardena family. Their commitment to providing exceptional service aligns perfectly with our core values of excellence, reliability, care, and integrity. Together, we will continue to support biopharma companies at the cutting edge of innovation to deliver life-changing therapies to patients worldwide."
“This expansion into North America is pivotal for Ardena as we continue to broaden our global footprint,” said Trochu.
“By adding advanced technologies such as Hot Melt Extrusion, we are not only enhancing our bioavailability improvement solutions but also aligning with our expertise in developing innovative nanomedicine drug delivery systems. This investment accelerates our scale of operations and breadth of offerings to better serve our fast-growing international client base.”

Role of GHO Capital on Current Acquisition

GHO Capital, Ardena’s private equity partner, has been instrumental in facilitating this acquisition as part of their ongoing commitment to accelerate Ardena’s transatlantic expansion.
The Partners at GHO Capital, commented, “We are excited to see this high-impact acquisition come to fruition. It significantly enhances Ardena’s technological and market capabilities across key regions, positioning the company for sustained value creation and long-term success under Jeremie’s leadership."

The transaction is expected to close in early 2025, subject to regulatory approvals and other customary closing conditions.

About the Company: Ardena

Ardena is a leading contract development and manufacturing organization in advanced drug development of new, innovative, and complex molecules.
Ardena’s mission is to enable current and next-generation therapies to get into the clinic and to patients faster.